Tempest Therapeutics (NASDAQ:TPST) Earns Outperform Rating from William Blair

Tempest Therapeutics (NASDAQ:TPST)‘s stock had its “outperform” rating reissued by investment analysts at William Blair in a report issued on Wednesday,RTT News reports.

Separately, HC Wainwright restated a “buy” rating and set a $47.00 price objective on shares of Tempest Therapeutics in a research note on Wednesday. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $20.00.

Tempest Therapeutics Stock Performance

Shares of NASDAQ TPST opened at $0.97 on Wednesday. The company has a quick ratio of 2.17, a current ratio of 2.17 and a debt-to-equity ratio of 0.12. The stock’s 50 day moving average price is $1.20 and its two-hundred day moving average price is $1.96. Tempest Therapeutics has a 52-week low of $0.86 and a 52-week high of $6.00. The stock has a market capitalization of $24.45 million, a P/E ratio of -0.63 and a beta of -1.78.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TPST. Fullcircle Wealth LLC acquired a new stake in Tempest Therapeutics in the third quarter worth $87,000. Empower Advisory Group LLC acquired a new position in Tempest Therapeutics during the 3rd quarter valued at about $49,000. Virtu Financial LLC grew its position in Tempest Therapeutics by 69.2% in the 1st quarter. Virtu Financial LLC now owns 28,574 shares of the company’s stock worth $112,000 after purchasing an additional 11,689 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Tempest Therapeutics in the second quarter valued at approximately $55,000. Institutional investors and hedge funds own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.